Add to ORKGThe background paper summarizes the evidence on the effectiveness and costs of prostate cancer screening and treatment in elderly men and explores the implications for Medicare of offering this preventive technology as a Medicare benefit
Background and Objectives The Goteborg randomised population-based prostate cancer screening trial d...
The objective of this study was to determine whether screening for prostate cancer (PC) reduces PC m...
ImportanceIn the United States, the lifetime risk of being diagnosed with prostate cancer is approxi...
"Preventive health services under Medicare.""OTA-BP-H-145"--P. [4] of cover."May 1995"--P. [4] of co...
PURPOSE: To discuss the issue of screening for prostate cancer in elderly individuals. The impact of...
In this paper OTA summarizes the evidence on the effectiveness and costs of colorectal cancer screen...
Abstract Background Multiple guidelines seek to alter rates of prostate-specific antigen (PSA)-based...
The total expenses on the early detection and further treatment of prostate cancer (PC) were analyze...
Prostate cancer early detection has progressed rapidly within the last decade, producing significant...
Objective To estimate costs on the Medicare Benefits Schedule (MBS) and the Pharmaceutical Benefits ...
textabstractBackground:Prostate cancer screening with prostate-specific antigen (PSA) has shown to r...
The results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial showed a...
CONTEXT. Although evidence-based guidelines recommend that physicians inform men about prostate canc...
In contrast to earlier studies which have used modelling to perform cost-effectiveness analysis, thi...
Free to read on journal website (may need to create free account first) Objectives: To apply the mos...
Background and Objectives The Goteborg randomised population-based prostate cancer screening trial d...
The objective of this study was to determine whether screening for prostate cancer (PC) reduces PC m...
ImportanceIn the United States, the lifetime risk of being diagnosed with prostate cancer is approxi...
"Preventive health services under Medicare.""OTA-BP-H-145"--P. [4] of cover."May 1995"--P. [4] of co...
PURPOSE: To discuss the issue of screening for prostate cancer in elderly individuals. The impact of...
In this paper OTA summarizes the evidence on the effectiveness and costs of colorectal cancer screen...
Abstract Background Multiple guidelines seek to alter rates of prostate-specific antigen (PSA)-based...
The total expenses on the early detection and further treatment of prostate cancer (PC) were analyze...
Prostate cancer early detection has progressed rapidly within the last decade, producing significant...
Objective To estimate costs on the Medicare Benefits Schedule (MBS) and the Pharmaceutical Benefits ...
textabstractBackground:Prostate cancer screening with prostate-specific antigen (PSA) has shown to r...
The results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial showed a...
CONTEXT. Although evidence-based guidelines recommend that physicians inform men about prostate canc...
In contrast to earlier studies which have used modelling to perform cost-effectiveness analysis, thi...
Free to read on journal website (may need to create free account first) Objectives: To apply the mos...
Background and Objectives The Goteborg randomised population-based prostate cancer screening trial d...
The objective of this study was to determine whether screening for prostate cancer (PC) reduces PC m...
ImportanceIn the United States, the lifetime risk of being diagnosed with prostate cancer is approxi...